Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Xiaojun Zhou is active.

Publication


Featured researches published by Xiaojun Zhou.


Modern Pathology | 2009

Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis

Yingchun Dong; Jiandong Wang; Zhen Sheng; Guoli Li; Henghui Ma; Xulin Wang; Ru-Song Zhang; Guangming Lu; Qiuju Hu; Haruhiko Sugimura; Xiaojun Zhou

The Eph gene family has important roles in the developmental processes and may also be involved in the initiation, progression, and metastasis of certain types of cancers. In the present study, quantitative real-time reverse-transcriptase PCR was performed to detect the expression of EphA1 transcript in 5 colon cancer cell lines and 75 colorectal carcinomas. Immunohistochemical staining was used to check the expression of EphA1 protein in 20 colorectal adenomas and in 111 colorectal carcinomas specimens. EphA1 protein expression was not completely consistent with transcript expression. EphA1 protein was expressed in all adenomas and reduced in 54% colorectal cancers. Reduced expression of EphA1 protein occurred more often in male patients (P=0.028) and in patients with poor differentiation (P=0.027), greater depth of wall invasion (P=0.003), lymph node metastasis (P=0.034), and advanced tumor stage (P=0.003). Patients with reduced EphA1 expression had a poor overall survival (P=0.059). Reduced EphA1 expression in patients over 55 years or with rectal cancers and sigmoid colon cancers is associated with a poor overall survival (P=0.034 and 0.015, respectively). Our data indicate that the EphA1 may play different roles during the different stages of colorectal carcinoma progression.


The American Journal of Surgical Pathology | 2015

PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.

Qiu Rao; Qin Shen; Qiu-yuan Xia; Zi-yu Wang; Biao Liu; Shan-shan Shi; Qun-Li Shi; Hong-lin Yin; Bo Wu; Sheng-bing Ye; Li Li; Jie-yu Chen; Min-hong Pan; Qing Li; Rui Li; Xuan Wang; Ru-Song Zhang; Bo Yu; Henghui Ma; Zhen-feng Lu; Xiaojun Zhou

An increasing number of TFE3 rearrangement–associated tumors, such as TFE3 rearrangement–associated perivascular epithelioid cell tumors (PEComas), melanotic Xp11 translocation renal cancers, and melanotic Xp11 neoplasms, have recently been reported. We examined 12 such cases, including 5 TFE3 rearrangement–associated PEComas located in the pancreas, cervix, or pelvis and 7 melanotic Xp11 translocation renal cancers, using clinicopathologic, immunohistochemical, and molecular analyses. All the tumors shared a similar morphology, including a purely nested or sheet-like architecture separated by a delicate vascular network, purely epithelioid cells displaying a clear or granular eosinophilic cytoplasm, a lack of papillary structures and spindle cell or fat components, uniform round or oval nuclei containing small visible nucleoli, and, in most cases (11/12), melanin pigmentation. The levels of mitotic activity and necrosis varied. All 12 cases displayed moderately (2+) or strongly (3+) positive immunoreactivity for TFE3 and cathepsin K. One case labeled focally for HMB45 and Melan-A, whereas the others typically labeled moderately (2+) or strongly (3+) for 1 of these markers. None of the cases were immunoreactive for smooth muscle actin, desmin, CKpan, S100, or PAX8. PSF-TFE3 fusion genes were confirmed by reverse transcription polymerase chain reaction in cases (7/7) in which a novel PSF-TFE3 fusion point was identified. All of the cases displayed TFE3 rearrangement associated with Xp11 translocation. Furthermore, we developed a PSF-TFE3 fusion fluorescence in situ hybridization assay for the detection of the PSF-TFE3 fusion gene and detected it in all 12 cases. Clinical follow-up data were available for 7 patients. Three patients died, and 2 patients (cases 1 and 3) remained alive with no evidence of disease after initial resection. Case 2 experienced recurrence and remained alive with disease. Case 5, a recent case, remained alive with extensive abdominal cavity metastases. Our data suggest that these tumors belong to a single clinicopathologic spectrum and expand the known characteristics of TFE3 rearrangement–associated tumors.


International Journal of Surgical Pathology | 2011

Renal cell carcinoma in children and young adults: clinicopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up.

Rao Q; Jie-yu Chen; Jiandong Wang; Henghui Ma; Hangbo Zhou; Zhen-feng Lu; Xiaojun Zhou

To further study the characteristics of renal cell carcinoma (RCC) in young patients and better define their biological features, 46 RCCs of patients younger than 25 years were morphologically and immunohistochemically characterized with follow-up. Loss of heterozygosity (LOH) analysis of the von Hippel—Lindau (VHL) gene region and screening for VHL gene mutations were performed in all tumors. Applying the 2004 WHO classification for RCC, there were 19 Xp11.2 translocation RCCs, 9 clear cell RCCs, 17 papillary RCCs, and 1 unclassified RCC. All 19 Xp11.2 translocation RCCs showed moderate to strong immunoreactivity for TFE3. None had TFEB immunoreactivity. One Xp11.2 translocation RCC had an unreported morphology with empty or ground glass nuclei, occasional nuclear grooves, inconspicuous nucleoli and abundant mucinous material in stroma.VHL gene analysis revealed deletions at 3p25-26 in 1 clear cell RCC and 1 papillary type 2 RCC. The papillary type 2 RCC was also presented with a family history of VHL disease and found a germline mutation G → C on a splicing site at position 553+5. The present case widens the spectrum of microscopic features to be found in VHL-associated RCC. There were no VHL mutations in the remaining 45 RCCs. Statistical analysis of stage and outcome revealed that TFE+ pediatric RCCs were significantly more frequently associated with a higher pTNM pT3/pT4 stage and a poorer outcome than TFE-RCCs (P < .05). Owing to the already known aggressive behavior of these Xp11.2 translocation RCCs, patients with TFE+ pediatric RCCs should benefit from a stricter follow-up.


Oncology | 2007

Loss of expression of EphB1 protein in gastric carcinoma associated with invasion and metastasis.

Jiandong Wang; Yingchun Dong; Zhen Sheng; Henghui Ma; Guoli Li; Xulin Wang; Guangming Lu; Haruhiko Sugimura; Jie Jin; Xiaojun Zhou

Objective:EphB1 is a member of the Eph family of receptor tyrosine kinases that is involved in embryonic nervous and vascular system development. Over- or underexpression of certain Eph receptors has been found in some cancer samples compared to normal tissue. Expression of Eph receptors is related to malignant transformation, metastasis, differentiation, and prognosis of cancers. Recently, the EphB subfamily has been shown to be involved in the tumorigenesis of colorectal cancer. In the present study, expression of the EphB1 transcript and protein in gastric carcinoma samples was determined to investigate the roles of EphB1 in development, progress and prognosis of gastric carcinoma. Methods: Quantitative real-time reverse transcriptase-polymerase chain reaction and immunohistochemical staining were used. Results: The EphB1 transcript was overexpressed in 68.9% (42/61) and underexpressed in 14.8% (9/61) of cases. However, the expression of protein was greatly different from the transcript expression, with overexpression and underexpression being 17.2% (10/58) and 44.8% (26/58), respectively. In addition, we showed that underexpression of EphB1 protein is significantly associated with invasion, stage and metastasis in gastric carcinomas. Conclusion: EphB1 may have a tumor-suppressive role in gastric cancer.


Human Pathology | 2013

Immunostaining with EGFR mutation–specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples

Xiangshan Fan; Biao Liu; Haodong Xu; Bo Yu; Shan-shan Shi; Jin Zhang; Xuan Wang; Jiandong Wang; Zhen-feng Lu; Henghui Ma; Xiaojun Zhou

Mutation analysis of epidermal growth factor receptor (EGFR) is essential in determining the therapeutic strategy for lung adenocarcinoma. Immunohistochemical (IHC) staining with EGFR mutation-specific antibodies of del E746-A750 in exon 19 and L858R in exon 21 has been evaluated in resection specimens in a few studies but rarely in biopsy samples. A total of 169 cases (78 biopsies and 91 resected specimens) of lung adenocarcinoma with EGFR mutation status predefined by direct DNA sequencing were histologically examined, and IHC was performed using EGFR mutation-specific antibodies of del E746-A750 and L858R. The cases with positive results by IHC but negative results by direct DNA sequencing were examined by amplified refractory mutation system. Our results showed that the frequency of EGFR mutations for both E746-A750 deletion and L858R mutation was 38.5% (65/169) by DNA sequencing or amplified refractory mutation system and 34.3% (58/169) by IHC in lung adenocarcinomas. Based on molecular test results, the overall sensitivity, specificity, positive predictive value, and negative predictive value of IHC using these 2 antibodies in all (biopsy/resection) cases were 87.7% (80%/94.3%), 99.0% (97.9%/100%), 98.3% (96%/100%), and 92.8% (88.7%/96.6%), respectively. Lung adenocarcinomas with a predominant acinar, papillary, lepidic, or solid growth pattern more often harbor EGFR mutation of del E746-A750 or L858R. In conclusion, the immunostaining with EGFR del E746-A750 and L858R mutation antibodies is a reliable screening method with high specificity and sensitivity for identifying the EGFR mutation in both resected and biopsied lung adenocarcinomas.


Journal of International Medical Research | 2009

Expression of CD34, α-Smooth Muscle Actin and Transforming Growth Factor-β1 in Squamous Intraepithelial Lesions and Squamous Cell Carcinoma of the Cervix

Q Li; W Huang; Xiaojun Zhou

This retrospective study investigated CD34, α-smooth muscle actin (α-SMA), and transforming growth factor-β1 (TGF-β1) expression in stromal cells of cervical intraepithelial neoplasias (CINs; n = 30), invasive cervical squamous cell carcinomas (SCCs; n = 38) and adjacent normal cervix. Normal cervix and CINs contained diffuse CD34-positive stromal cells but no α-SMA-positive myofibroblasts. In contrast, 34 of 38 SCCs were free of CD34-positive stromal cells and all contained α-SMA-positive stromal myofibroblasts; adjacent normal tissue contained CD34-positive stromal cells and no α-SMA-positive myofibroblasts. More intense TGF-β1 expression was observed in SCC cells than in normal cervical epithelium or CINs. This study shows that the disappearance of CD34-positive stromal cells and appearance of α-SMA-positive stromal myofibroblasts may be associated with transformation of cervical CIN to SCC. These findings support the suggestion that over-production of TGF-β1 in SCC cells is one potential mechanism mediating the transformation of stromal cells to myofibroblasts in cervical carcinogenesis.


Histopathology | 2015

Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours

Qiu Rao; Qiu-yuan Xia; Zi-yu Wang; Li Li; Qin Shen; Shan-shan Shi; Xuan Wang; Biao Liu; Yan-fen Wang; Qun-Li Shi; Henghui Ma; Zhen-feng Lu; Yan He; Ru-Song Zhang; Bo Yu; Xiaojun Zhou

Malignant rhabdoid tumours (MRTs) are highly aggressive malignancies of early infancy characterized by inactivation of SMARCB1, a core member of the SWI/SNF chromatin‐remodelling complex. The aim of this study was to explore the status of multiple key subunits of the SWI/SNF complex in MRTs.


Pathobiology | 2008

EphB1 is underexpressed in poorly differentiated colorectal cancers.

Zhen Sheng; Jiandong Wang; Yingchun Dong; Henghui Ma; Hangbo Zhou; Haruhiko Sugimura; Guangming Lu; Xiaojun Zhou

Background: Over- or underexpression of certain Eph receptors has been associated with tumorigenesis of some types of cancer. EphB1 is a member of receptor tyrosine kinases of the EphB subfamily involved in the development, progress and prognosis of colorectal cancers. The expression levels of EphB1 in colon cancer cell lines and human colorectal carcinoma specimens were determined and association of EphB1 expression with clinicopathological parameters was analyzed. Methods: Quantitative real-time reverse transcription polymerase chain reaction and immunohistochemistry were used. Results: The EphB1 transcript is expressed in all colon cancer cell lines tested. However, there is marked variability in the expression of the EphB1 transcripts and proteins among colorectal carcinoma specimens. Reduced expression of EphB1 in colorectal cancers more often occurred in poorly differentiated and mucinous adenocarcinomas than in well- and moderately differentiated adenocarcinomas. Further, cancer cells with a low level of EphB1 protein showed more invasive power. Conclusion: Our data indicate that EphB1 may have roles in the pathogenesis and development of colorectal cancer.


Human Pathology | 2014

Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis.

Li Li; Xiangshan Fan; Qiu-yuan Xia; Qiu Rao; Biao Liu; Bo Yu; Qun-Li Shi; Zhen-feng Lu; Xiaojun Zhou

The loss of INI1 (SMARCB1) expression, caused by SMARCB1 (INI1, SNF5L4, BAF47) inactivation, frequently occurs in epithelioid sarcoma (ES) and could aid in confirming the diagnosis. Except for INI1, the expression of switch in mating type/sucrose nonfermentation complex members in ES has never been examined. In this study, the expression of key subunits of this complex-INI1, BRG1 (SMARCA4), BRM (SNF2L2, SMARCA2), PBRM1 (hPB1, BAF180), and BAF155 (SMARCC1)-was analyzed in 23 ES cases: 15 conventional and 8 proximal type. All of the cases were reviewed and reclassified by hematoxylin-eosin staining and immunostaining for cytokeratin AE1/3, epithelial membrane antigen, CD34, vimentin, and INI1 expression. Of the 23 ES cases, 19 (82.6%) showed a loss of PBRM1, and 18 (78.3%), a loss of INI1. In most cases (17, 73.9%), loss of INI1 and PBRM1 expression was observed. The pattern of PBRM1 expression was similar to that of INI1, that is, not correlated with changes in cellular morphology. The concurrent loss of BRM, PBRM1, and INI1expression was detected in 2 cases with pure rhabdoid tumor features. The frequent observation of concurrent loss of INI1 and PBRM1 suggests that certain switch in mating type/sucrose nonfermentation complex components might act synergistically in the pathogenesis of ES by unknown mechanisms and that these components could provide new targets for therapy. The usefulness of PBRM1 as a biomarker of ES and its mechanism in ES require further investigation. Loss of BRM in ES with pure rhabdoid features suggests that BRM might be involved in the underlying mechanisms of this type of ES.


Surgery Today | 2009

Primary adenosquamous carcinoma of the colon: Report of five cases

Yingchun Dong; Jiandong Wang; Henghui Ma; Hangbo Zhou; Guangming Lu; Xiaojun Zhou

Primary adenosquamous cell carcinomas (Ad-SCCs) of the colon and rectum are rare malignancies with a poor prognosis, in comparison to adenocarcinoma alone. Different roles of human papilloma virus (HPV) in its pathogenesis have been reported and the role of P16 in Ad-SCCs has not been explored. This report presents five cases of Ad-SCC of the colon to explore the clinicopathological features and the roles of P16, HPV 6/11, and 16/18. There was no confirmed evidence to support the relationship between the infection of HPV 6/11, 16/18, and pathogenesis of Ad-SCC of the colon. P16 overexpression was not related to HPV carcinogenesis and there might be another mechanism of P16 upregulation in Ad-SCC of the colon.

Collaboration


Dive into the Xiaojun Zhou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge